Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Plasma dispositions of ivermectin and doramectin in dogs
Although they are not licensed for the use in small animals, ivermectin, moxidectin and doramectin injectable formulations are widely used to treat certain ectoparasites in dogs. Are there major differences between doramectin and the `classic` ivermectin? An important question which was evaluated in Turkey.

This study evaluates the comparative plasma dispositions of ivermectin (IVM) and doramectin (DRM) following oral and subcutaneous administration (200 microg/kg) over a 40-day period in dogs.

Twenty bitches were allocated by weight in to four groups (Groups I-IV) of five animals each. Animals in the first two groups (Groups I and II) received orally the injectable solutions of IVM and DRM, respectively, at the dose of 200 microg/kg bodyweight.

The other two groups (Groups III and IV) received subcutaneously injectable solutions at the same dose rate.

Blood samples were collected between 1h and 40 days after treatment and the plasma samples were analysed by high performance liquid chromatography (HPLC) using fluorescence detection.

The results indicated that IVM produced a significantly higher maximum plasma concentration (C(max): 116.80+/-10.79 ng/ml) with slower absorption (t(max): 0.23+/-0.09 day) and larger area under the concentration versus time curve (AUC: 236.79+/-41.45 ng day/ml) as compared with DRM (C(max): 86.47+/-19.80 ng/ml, t(max): 0.12+/-0.05 day, AUC: 183.48+/-13.17 ng day/ml) following oral administration of both drugs; whereas no significant differences were observed on the pharmacokinetic parameters between IVM and DRM after subcutaneous administrations.

In addition, subcutaneously given IVM and DRM presented a significantly lower maximum plasma concentration (C(max): 66.80+/-9.67 ng/ml and 54.78+/-11.99 ng/ml, respectively) with slower absorption (t(max): 1.40+/-1.00 day and 1.70+/-0.76 day, respectively) and larger area under the concentration versus time curve (AUC: 349.18+/-47.79 ng day/ml and 292.10+/-78.76 ng day/ml, respectively) as compared with the oral administration of IVM and DRM, respectively.

No difference was observed for the terminal half-lives ((t(1/2lambda(z)) and mean residence times (MRT) of both molecules.

Considering the pharmacokinetic parameters, IVM and DRM could be used by the oral or subcutaneous route for the control of parasitic infection in dogs.



Source: Gokbulut C, Karademir U, Boyacioglu M, McKellar QA. (2006): Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. In: Vet Parasitol. 2006 Feb 18;135(3-4):347-54.



Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Novel intratumoral therapy in canine transmissible venereal tumour
Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the immune status of the host. The aim was to investigate recombinant human interferon alpha‐2a (rhIFNα‐2a) and vincristine for treatment of CTVT.

  • Long-term outcome of dogs with primary immune-mediated thrombocytopenia
  • Computed tomographic arthrography of the canine shoulder joint members
  • Prognostic scoring system for dogs managed with hemodialysismembers
  • Sonography vs percutaneous palpation to identify targeted thoracolumbar intervertebral disc spacesmembers
  • Distribution of alveolar-interstitial syndrome in dogs and cats with respiratory distress members
  • Disorders of sex development in catsmembers
  • Core ocular surface microbiome in dogsmembers
  • ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics members
  • MRI imaging of masticatory muscles in basset houndsmembers
  • Mucosal microbiota, gastrointestinal inflammation and small cell intestinal lymphoma in cats members
  • Efficacy of pentamidine analogue 6 in dogs with chronic atrial fibrillationmembers
  • Tick-borne relapsing fever in various speciesmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved